Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Rite Aid Corporation    RAD

Delayed Quote. Delayed  - 09/30 10:01:34 pm
7.69 USD   +1.59%
09/29 RITE AID : DreamShip Hot Air Balloon, Designed by Children of Americ..
09/29 RITE AID : to honor local scholarship recipients on Friday
09/28 RITE AID : How a pharmacy helped sons of late Air Force captain
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

Deductibles For Employer Healthcare Plans Soar, Kaiser Family Foundation Reports

share with twitter share with LinkedIn share with facebook
share via e-mail
09/29/2016 | 05:44pm CEST

By a News Reporter-Staff News Editor at Clinical Trials Week -- While spending by families for their annual employer-sponsored health insurance coverage grew an average of only three percent this year - that rate was made possible by a large increase in the movement of workers into high deductible insurance plans, the Kaiser Family Foundation reported earlier this week (see also Conceivex, Inc.).

At the same time, the successful introduction of an insurance-covered first step at-home treatment for infertility continues to hold down healthcare costs for employers, insurers, and consumers alike. The Conception Kit® at-home system is an FDA cleared, drug- and hormone-free infertility treatment that couples can get with a prescription for a $30-$75 co-pay (under many insurance plans). About 60 percent of insured individuals in the U.S. already have reimbursable access to the Conception Kit through their pharma benefits manager (including Express Scripts, CVS/Caremark, and others) and it is available at more than 65,000 pharmacies in the U.S., including Walmart, Target, Walgreens, and Rite Aid.

The FDA required clinical trials on placement of the Conception Kit's Conception Cap (a cervical cap used for insemination at home) and instructions by patients. During the trials, 24 percent of the patients got pregnant during the first 30 days.

By comparison, many historic infertility treatment options can prove costly. For example, a single cycle of in-vitro fertilization (IVF) costs $12,500 on average, according to the American Society for Reproductive Medicine, and is not always covered by insurance. And while advancements have been made in IVF treatment, patients who elect this route to address infertility still face risks, including multiple births as well as premature births that can land newborns in the Neonatal Intensive Care Unit (NICU), and thereby drive up overall healthcare costs. The Conception Kit provides three months of supplies (including 24 ovulation predictors, three pregnancy tests, along with the Conception Cap, and a number of additional proprietary aides) - that, in many cases, would cost more over-the-counter than the total amount of the co-pay. Even without a co-pay, the entire Conception Kit is available for $360.

"With out of pocket healthcare expenses continuing to climb, the Conception Kit offers millions of couples with an opportunity that they never had before to start a family," Michael La Vean, President and Founder of Conceivex, maker of the Conception Kit, said. About Conceivex, Inc. Conceivex, Inc., manufactures and distributes the Conception Kit® at-home system, a safe, effective, FDA cleared, and reasonably priced healthcare product that helps couples overcome infertility in the privacy of their own home. The Conception Kit , which is covered by many insurance plans (including Express Scripts and CVS/Caremark), is obtainable with a prescription at Walmart, Target, Walgreens, Rite Aid, and 65,000 pharmacies nationwide. Find out more at www.conceptionkit.com, on Facebook at https://www.facebook.com/conceptionkit/, and on LinkedIn. View source version on businesswire.com: http://www.businesswire.com/news/home/20160916005067/en/

Keywords for this news article include: Conceivex Inc.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2016, NewsRx LLC

(c) 2016 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
09/29 Deductibles For Employer Healthcare Plans Soar, Kaiser Family Foundation Repo..
09/29 RITE AID : DreamShip Hot Air Balloon, Designed by Children of America’s Mi..
09/29 RITE AID : to honor local scholarship recipients on Friday
09/28 RITE AID : How a pharmacy helped sons of late Air Force captain
09/27 RITE AID : Expands Naloxone Dispensing Program in Four Additional States
09/27 RITE AID : Flu shot clinic in North Tonawanda
09/26 RITE AID CORPORATION : Post Earnings Coverage as Rite Aid Q2 Topline Registers G..
09/23DJRITE AID : Business Watch -- WSJ
09/22DJRITE AID : Same-Store Sales Fall Amid Generics Pressure
09/22 RITE AID CORP : Results of Operations and Financial Condition, Financial Stateme..
More news
Sector news : Retail - Drugs without Grocery
09/30DJJ SAINSBURY : Sainsbury Appoints Walgreens Boots' Simon Roberts As Retail Direct..
09/22DJRITE AID : Same-Store Sales Fall Amid Generics Pressure
09/15 MCKESSON : German antitrust watchdog raids drugs distributors
09/14DJGoogle Acquisition Apigee's Revenue Climbs
09/14DJGoogle Acquisition Apigee's Revenue Climbs
More sector news : Retail - Drugs without Grocery
News from SeekingAlpha
09/30 RITE AID/WALGREENS BOOTS ALLIANCE DE : Potential Gains Gone Up, Risk Not Much
09/28 Walmart's Next Move Against Amazon
09/28 PE firms snooze on 650-unit Walgreens sale
09/25 Insights From Rite Aid's 2nd Quarter
09/23 RITE-AID : We Just Don't Know
Financials ($)
Sales 2017 32 856 M
EBIT 2017 680 M
Net income 2017 147 M
Debt 2017 6 848 M
Yield 2017 -
P/E ratio 2017 53,55
P/E ratio 2018 34,25
EV / Sales 2017 0,45x
EV / Sales 2018 0,43x
Capitalization 8 067 M
More Financials
Duration : Period :
Rite Aid Corporation Technical Analysis Chart | RAD | US7677541044 | 4-Traders
Full-screen chart
Technical analysis trends RITE AID CORPORATION
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus HOLD
Number of Analysts 7
Average target price 8,83 $
Spread / Average Target 15%
Consensus details
EPS Revisions
More Estimates Revisions
John T. Standley Chairman & Chief Executive Officer
Kenneth A. Martindale President & Chief Operating Officer
Darren W. Karst SEVP, Chief Financial & Administrative Officer
Steve Rempel Chief Information Officer & Senior Vice President
Joseph B. Anderson Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ORIOLA KD OYJ-5.56%829
More Results